Laurent Ségalat

Loss-of-function genetic diseases and the concept of pharmaceutical targets

Laurent Ségalat, 2007, Orphanet Journal of Rare Diseases.

Gene expression profiling studies on Caenorhabditis elegans dystrophin mutants dys-1(cx-35) and dys-1(cx18).

David B Sattelle, Laurent Ségalat, Pascal Lescure, 2006, Genomics.

Metabolic profiling strategy of Caenorhabditis elegans by whole-organism nuclear magnetic resonance.

Lyndon Emsley, Martial Piotto, Pierre Toulhoat, 2009, Journal of proteome research.

Caenorhabditis elegans as a chemical screening tool for the study o f neuromuscular disorders. Manual and semi-automated methods.

Laurent Ségalat, L. Ségalat, M. Carre-Pierrat, 2012, Methods.

High‐throughput screening and small animal models, where are we?

Laurent Ségalat, L. Ségalat, J. Giacomotto, 2010, British journal of pharmacology.

Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans

Jean-Marc Simon, Thomas Witzel, Laurent Ségalat, 2004, Neuromuscular Disorders.

Invertebrate animal models of diseases as screening tools in drug discovery.

Laurent Ségalat, L. Ségalat, 2007, ACS chemical biology.